GSK deal drives rise in Codexis' guidance; Jubilant weathers FDA criticisms;

> Codexis raised its guidance for 2014 on the back of its tech collaboration with GlaxoSmithKline. Release

> Jubilant Life Sciences reported an uptick in sales despite its CMO business being affected by its run in with FDA. Results (PDF)

> Indian drugmaker S Kant Healthcare could open a production plant in Malta. News

> UCB is reportedly considering selling its U.S. specialty generics unit, which runs a 400,000-square-foot plant in Seymour, Indiana. Article

And Finally... A report tipped the value of the U.S. pharmaceutical excipient market to hit $2 billion by 2018. Sales are expected to grow by 4.3% a year, partly driven by 1.9% annual increases in volume. Report